JN Nova Pharma Secures Health Canada Approval for Phase I Trial of its Long COVID Therapy

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

JN Nova Pharma, a clinical-stage biopharmaceutical company, has received clearance from Health Canada to initiate a Phase I clinical trial for its proprietary, first-in-class Long COVID therapy. This milestone marks a significant step forward in addressing an urgent and underserved global medical need addressing $50B market.

JN Nova Pharma is an OBIO® member and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Neuropeutics Receives the Inaugural AbbVie Biotech Innovators Award
Next

The Time is Right to Invest in Canadian Biotechnology and Stop Subsidizing Foreign Biotechnology Companies